Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
NCT00243191 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. As of 21 Nov 2026, it is completed. It studies Imatinib in Dermatofibrosarcoma Protuberans. The registry lists an enrollment of 18 participants at 4 sites in 1 country. The registry lists a start date of 31 May 2006 and a primary completion date of 30 Sept 2009. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00243191 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Sarcoma Alliance for Research through Collaboration |
| Enrollment | 18 |
| Registered sites | 4 |
| Countries | 1 |
| Conditions | Dermatofibrosarcoma Protuberans |
| Drugs | Imatinib |
| Start | 31 May 2006 |
| Primary completion | 30 Sept 2009 |
| Study completion | 30 Sept 2009 |
| Last update posted | 29 Mar 2012 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- H. Lee Moffitt Cancer Center
Tampa
- University of Michigan Comprehensive Cancer Center
Ann Arbor
- Pennsylvania Onc/hem Assoc.
Philadelphia
- Md Anderson Cancer Center
Houston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00243191
Each answer restates registry values shown on this page.
What is NCT00243191?
NCT00243191 is a phase 2 interventional trial sponsored by Sarcoma Alliance for Research through Collaboration. It studies Imatinib in Dermatofibrosarcoma Protuberans.
Who leads NCT00243191?
The registry names Scott Schuetze, MD, PhD (principal investigator, University of Michigan) as the overall official.
Where does NCT00243191 run?
The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00243191 study?
The registered drug and biological interventions are Imatinib.
When did NCT00243191 end?
The registry lists a primary completion date of 30 Sept 2009 and a study completion date of 30 Sept 2009. The sponsor last updated the record on 29 Mar 2012.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.